secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2026-09-23T20:01:32+00:00
Accession:  0001213900-26-102611
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron's ELPIS II Phase 2b misses primary endpoint; strategic review initiated
--------------------------------------------------------------------------------

- ELPIS II missed primary endpoint: RVEF change from baseline -0.7 pp (95% CI -7.3 to 5.9, p=0.8336) in ITT.
- Exploratory: no deaths in laromestrocel arm vs 1 control at 12 months; transplant-free survival 1 vs 2 events.
- MACE ~31% fewer (12 vs 19 events) but not statistically significant; no new safety signals across 644 patients.
- Company to explore all options to maximize shareholder value, engaging an investment bank and cost containment.
- Longevity/frailty: Phase 2b data published in Cell Stem Cell Feb 2026; $1M XPRIZE Milestone 2 Award, up to $81M grand prize.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/0001213900-26-102611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/ea0306147-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-102611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer